Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups such as Theravance and Aspira [1] - Brendan is a co-founder of 1200 Pharma, which received significant investment in the eight figures as it spun out of Caltech [1] Group 2 - The article expresses the author's own opinions and indicates a beneficial long position in GILD shares [2] - There is no compensation received for the article other than from Seeking Alpha, and there is no business relationship with any mentioned company [2] Group 3 - The article does not provide any investment recommendations or advice, emphasizing that past performance does not guarantee future results [4]